Akston’s NGF-Targeting Ambifect® Candidates Demonstrate Clinically Meaningful Osteoarthritis Pain and Function Improvements Comparable to Bedinvetmab in Head-to-Head Canine Study

Data presented at the 2026 American College of Veterinary Internal Medicine (ACVIM) Forum showed that AKS-548d and AKS-734 induced sustained anti-NGF antibody responses, functional neutralization of NGF binding to TrkA, clinically meaningful reductions in canine osteoarthritis pain, and improvements in function, with a well-tolerated safety profile. In a randomized exploratory head-to-head study in dogs with […]